Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block

• Status: Completed
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

TAP-block has been shown to be a safe and effective postoperative analgesia method in a variety of general. Dexmedetomidine is a selective α2 agonist with 8 times more affinity for α2 adrenergic receptors compared to clonidine and possesses all the properties of α2 agonist without respiratory depression. Dexmedetomidine has been focus of interest for its broad spectrum (sedative, analgesic and anesthetic sparing) properties, making it a useful and safe adjunct in many clinical applications.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Bupivacaine; Dexmedetomidine

Criteria

Inclusion Criteria:

• 24 ASA I-II

• patients (age 18-60 years

• weight 50-89 kg

Exclusion Criteria:

• a known allergy to the study drugs

• significant cardiac

• respiratory, renal or hepatic diseases

• bleeding diathesis